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Abstract
Background Circulating tumor cells (CTC) in the peripheral blood in women with breast cancer has been found to be an 
indicator of prognosis before the start of systemic treatment. The aim of this study is the assessment of specific cytokine 
profiles as markers for CTC involvement that could act as independent prognostic markers in terms of survival outcome for 
breast cancer patients.
Methods Patients selected for this study were defined as women with breast cancer of the SUCCESS study. A total of 200 
patients’ sera were included in this study, 100 patients being positive for circulating tumor cells (CTC) and 100 patients being 
CTC negative. The matching criteria were histo-pathological grading, lymph node metastasis, hormone receptor status, TNM 
classification, and patient survival. Commercial ELISA with a multi cytokine/chemokine array was used to screen the sera 
for Interleukin 15 (IL-15) and eotaxin.
Results Statistically significant concentrations were exposed for IL-15 levels regardless of the CTC-Status, lymph node 
involvement, or hormone receptor status. Significantly enhanced serum IL-15 concentrations were observed in those patients 
with worse overall survival (OS) and disease-free survival (DFS). Elevated serum concentrations of IL-15 significantly cor-
relate with patients diagnosed with Grade 3 tumor and worse OS. In contrast, patients with a Grade 3 tumor with a favourable 
OS and DFS demonstrated significantly decreased IL-15 values. The CTC negative patient subgroup with a favourable OS 
and DFS, showed statistically significant elevated eotaxin values.
Conclusion These findings suggest a potential functional interaction of increased IL-15 concentrations in the peripheral 
blood of patients with a worse OS and DFS, regardless of prognostic factors at primary diagnosis. The increased levels of the 
chemokine eotaxin in CTC negative patients and a favourable OS and DFS, on the other hand, suggest that the overexpression 
inhibits CTCs entering the peripheral blood, thus emphasizing a significant inhibition of circulation specific metastasis. To 
sum up, IL-15 could be used as an independent prognostic marker in terms of survival outcome for breast cancer patients 
and used as an early indicator to highlight high-risk patients and consequently the adjustment of cancer therapy strategies.
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OS  Overall survival
AUC  Area under the curve
FEC  Fluorouracil-epirubicin-cyclo-phosphamide
NK  Natural killer
DC  Dendritic cells
HER2  Human epidermal growth factor receptor 2
Introduction
Breast cancer is the most common malignant tumor in 
women; yet invasive breast cancer is still considered one 
of the greatest challenges for experts to control and thereby 
improve the survival of patients [1]. The options for treat-
ment of breast cancer comprise targeted therapies, chemo-
therapy, surgery, radiotherapy, aromatase inhibitors, and 
hormone-receptor modulators [2–4]. Even though the 
options have advanced extremely over the past years, the 
consistently high mortality rate, due to tumor metastasis to 
the lymph node and vital organs, remains [5]. Its mortality 
is mostly due to distant metastatic growth [5, 6].
The expression ‘liquid biopsy’ describes the observation 
and evaluation of treatment effectiveness in patients with 
breast cancer and refers to molecular analysis of the tumor’s 
genetic structures based on circulating genetic material in 
the peripheral blood derived from circulating tumor cells 
(CTCs) [7, 8]. The technology for detecting CTCs has pro-
gressed from simple cell counting into advanced molecular 
subtyping [9], and as a minimally invasive method it could 
be of tremendous importance in the future for early can-
cer identification and disease monitoring. The correlation 
between poor prognosis and the detection of CTCs before 
the start of systemic treatment has been described previously 
[10]. CTCs in the peripheral blood have been determined 
to be a prognostic marker for reduced disease-free survival 
(DFS), distant DFS and overall survival (OS) before the start 
of systemic treatment in both metastatic and non-metastatic 
breast cancer [10–14]. As CTCs are believed to originate 
from the primary tumor and to acquire genetic heterogeneity 
during evolution, CTC values also provide complementary 
information concerning the treatment response [14]. The 
SUCCESS study was one of the first trials to determine the 
prognostic association of CTCs with poorer survival in early 
breast cancer, before the start of systemic adjuvant treat-
ment, and after adjuvant chemotherapy, in a large patient 
collective [15].
In order to understand the cause for CTC involvement, 
maturity, and outcomes, cytokine measurements in can-
cer therapy have become increasingly crucial [16]. As the 
involvement of the lymphatic system is known to play a 
key role in the progression of breast cancer [17], the aim 
of this study was the evaluation of Interleukin 15 (IL-15) 
and eotaxin as markers for CTC involvement in patients 
with the primary diagnosis of breast cancer. Cytokines 
and chemokines, through their tumor-promoting or tumor-
suppressive properties, leading to the expression of either 
pro-inflammatory or anti-inflammatory cytokines [18], 
are able to trigger cancer progression and are presumed 
to be an important prognostic factor in the presence of 
breast cancer tumors [19]. Helper T-lymphocyte matura-
tion depends on the arrangement of cytokines and results 
in the stimulation or suppression of critical cell derivation 
[20, 21]. One such pro-inflammatory cytokine is IL-15. 
IL-15 has early been identified as a 14–18 kDa protein 
[22]. The IL-15 structure produced in humans is described 
as a four α-helical bundle cytokine, positioned on chromo-
some 4q31 [22]. IL-15 was found to practice its biologi-
cal effects, exploiting two separate signalling pathways. 
One of these paths encloses the conventional binding and 
signalling through the IL-15 receptor α (IL-15Rα), β and 
γ chains [22, 23]. This pathway is of interest as it has 
been described to result in the up-regulation of natural 
killer cells and T-cell activity in the human immune sys-
tem [23–25]. The studies concerning IL-15 so far have 
already focused on its role concerning tumor genesis and 
its effect on proliferation, invasion, and metastasis produc-
tion. IL-15 has predominantly been investigated in haema-
tological malignancies [26–28] and is associated with a 
range of inflammatory disorders [25, 29]. The expression 
of IL-15 has been described as a protective factor in tumor 
genesis and against tumor progression in certain publica-
tions [30, 31], but in advanced solid cancers IL-15 expres-
sion acts contrarily thus contributing to disease progres-
sion [32–35]. Recently, studies demonstrated that IL-15 
detected in sera of patients could provide neoplastic cells 
with a selective growth advantage in inducting and pro-
moting certain types of malignancies [28, 36]. In regards 
to haematological malignancies, Cario et al. implied that 
IL-15 may increase cellular proliferation and is associ-
ated with poor prognosis in regards to relapse-free survival 
[37]. In a similar study by Chow et al., the serum levels 
of IL-15 were increased significantly in cancer patients 
compared to healthy individuals [38]. Eotaxin on the other 
hand is known to selectively recruit eosinophils, enhanc-
ing anti-tumor effects [39, 40].
The inconsistency of increased IL-15 levels acting both 
as a positive or negative marker in regard to tumor progres-
sion and survival outcome, could be explained by the role 
of dendritic cells (DCs) and their effect on the Immune sys-
tem. DCs are known to be one of the most potent types of 
antigen-presenting cells in the human body and are involved 
in the regulation of both distinctive and adaptive immune 
responses [41]. DCs could therefore be of major importance 
concerning the effectiveness of IL-15 and its influence on 
survival outcome, and should be considered for future 
studies.
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As no specific characteristics were described so far in 
relation to breast cancer, our goal was to examine the value 
of IL-15 in the T-lymphocyte immune response and the 
chemokine eotaxin, to reveal differences in the presence 
or absence in patients with breast cancer of the SUCCESS 
study; examining this with respect to CTC involvement, his-
topathological grading, lymph node status, hormone receptor 
type, OS, and DFS.
Detection of certain cytokine profiles and evaluation of 
their features can contribute to our better understanding of 
the disease, customized treatment options, and improved 
therapy observation. The tumor cell features in relation to 
cytokine profiles, their effect on the autoimmune response 
and changes in the microenvironment at the homing site, are 
of major importance for the future and therefore could be of 
use in generating new therapies.
Materials and methods
SUCCESS study design
SUCCESS was a prospective, randomized adjuvant 
study comparing three cycles of fluorouracil-epirubicin-
cyclo-phosphamide (FEC; 500/100/500 mg/m2) followed 
by 3 cycles of docetaxel (100 mg/m2) every 3 weeks vs. 
three cycles of FEC followed by 3 cycles of gemcitabine 
(1000 mg/m2 d1,8)-docetaxel (75 mg/m2) every 3 weeks. 
After the completion of chemotherapy, the patients were 
randomized a second time to receive either 2 or 5 years of 
zoledronate. Hormone receptor–positive women, moreover, 
received applicable endocrine treatment.
The translational research questions related to CTC analy-
sis, the blood sampling time points, and the methodology, 
were accordingly designed, and the prognostic value of the 
CTCs was described as a scientific objective of the study 
protocol. Eligible patients were defined as women with 
breast cancer (Lymph node positive subgroup and Lymph 
node negative subgroup with high risk traits including grade 
3 tumor, hormone receptor negative, age under 35, ≥ pT2) 
who agreed to participate in the SUCCESS study (www.
succe ss-studi e.de). The study was permitted by 37 German 
ethical boards (lead ethical board: LMU, Munich) and con-
ducted in agreement with the Declaration of Helsinki.
Blood sample collection for CTC enumeration
Blood samples for CTC enumeration were collected after 
study inclusion from 2090 consecutive patients after com-
plete resection of the primary tumor and before adjuvant 
chemotherapy and after written informed consent was 
acquired. Sixty-four patients were excluded because of test 
failure or a time intermission of more than 96 h between 
the blood collection and sample preparation. A follow-up 
evaluation after chemotherapy and before the beginning of 
endocrine or bisphosphonate treatment was available for 
a subgroup of 1492 patients (see homepage: https ://www.
succe ss-studi e.de).
The method was conducted as described by the SUC-
CESS Study group [15]. CTCs were investigated using 
the CellSearch System (Veridex, Jansen Diagnostics, NJ, 
USA). Peripheral blood was drawn into three CellSave tubes 
(30 ml), sent at room temperature to the central laboratory 
at the University of Munich, and examined within 96 h of 
collection.
The patient samples were then centrifuged for 10 min at 
800 × g. The plasma was removed, and a dilution buffer was 
supplemented. This combination was overlaid on 6 ml of 
Histopaque (Sigma, Steinheim, Germany) and centrifuged 
for 10 min at 400 × g. Subsequently, 7.5 ml of this sam-
ple enclosing the buffy coat were treated on the CellTracks 
AutoPrep system using the CellSearch Epithelial Cell Kit 
(Veridex). After immuno-magnetic enrichment with an 
antibody to Epithelial cell adhesion molecule (EpCAM), 
the cells were marked with fluorescent anti-cytokeratin 
(CK8,18,19–phycoerythrin) and anti-CD45 (CD45–allo-
phycocyan) antibodies, and 4,6-diamidino-2-phenyl-indole-
dihydrochloride was used to identify the intact cells.
Detection of CTCs
The identification and enumeration of CTCs were achieved 
using the CellTracks Analyzer II. CTCs were stated as 
nucleated cells lacking CD45 and expressing cytokeratin. 
All positive samples were assessed by two independent 
investigators. Samples with at least one CTC per 30 ml of 
blood were regarded as CTC-positive.
The blood of 84 persons with no clinical evidence of 
malignant disease was processed blind and used as a nega-
tive control. Four of these negative controls (4.9%) contained 
cells that fit the definition of epithelial cells and which could 
be interpreted as CTCs (one control had one, two controls 
had two, and one control had three epithelial cells).
Patients included
In this study 200 patients of the SUCCESS study were 
included and assigned into two groups: 100 Patients were 
CTC-positive (Group 1) and the other 100 patients were 
CTC-negative (Group 2). These two groups were framed and 
investigated accordingly. Patients from, respectively, groups 
were matched into pairs of two according to histo-patholog-
ical grading, lymph node involvement, hormone receptor 
type, and TNM classification. Furthermore, patients were 
matched according to OS (survived patients vs. deceased 
patients) at the end of the follow-up period. Out of 200 
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patient samples that were investigated, 160 patients were 
still alive at last observation at end of therapy and 40 patients 
had died during therapy. The groups investigated included 
98 patients with tumor graded G2 and 102 patients graded 
G3. Matching criteria of the patient collective did not allow 
participants with G1 tumors (see Table 1). Tumor stage of 
the anamnestic diagnosis was classified according to the 
TNM-classification, which was conducted according to the 
WHO System [42]. The matching of patients was performed 
according to the criteria at the time of primary diagnosis. 
The histo-pathological grading was classified according to 
the Bloom and Richardson system classification [43].
Follow‑up and patient evaluation
The median follow-up was 65 months (range 1–96 months). 
All time-to-event intervals were measured from time of the 
primary diagnosis to the date of the event or the date of 
the last adequate follow-up in case no event was reported. 
Patient outcomes were examined in terms of both DFS 
and OS. The patients were monitored at the study sites at 
3-month intervals for the first 3 years, followed by every 
6 months thereafter. The follow-up involved clinical exami-
nation and symptom-driven analyses, if necessary, at each 
visit, and mammography every 6 months. The collected data 
were acquired from the electronic case record forms of the 
SUCCESS study [15].
Cytokine determination
For the measurement of cytokines, a commercial enzyme-
linked immunosorbent assay (ELISA) was used to screen 
the blood serum samples for IL-15 and eotaxin. The ELISA 
was preformed with recently developed multi cytokine/
chemokine arrays acquired by Meso Scale  Discovery® 
(Rockville, MD, USA). We used anti-species MULTI-
ARRAY 96-well plates for the development of a sandwich 
immunoassay. Each assay in the panel was verified individu-
ally for the Specificity by running single calibrators with 
single detection antibodies. Non-specific binding levels were 
less than 0.5% for all assays. The 10 spot MULTI-SPOT 
plates were pre-coated with capture antibodies on independ-
ent and well defined spots that allowed us to immobilize a 
primary capture antibody against our protein of interest—
specific for one of each vascular marker. Standards and sam-
ples were added to the appropriate wells. A standard curve 
was furthermore run with each assay. We firstly added the 
blood serum, calibrator and control. Subsequently we incu-
bated at room temperature with shaking for 2 h. After elimi-
nating excess samples from the well with wash buffer, we 
added the detection (anti-target) antibody conjugated with 
electrochemiluminescent labels over the course of two incu-
bation periods. During the incubation period, where time 
slots differed in each test, the target present in the sample 
bound to the capture antibody, which was immobilized on 
the working electrode surface by the anti-species antibody. 
Recruitment of the labelled detection antibody by the bound 
target completed the sandwich. After a second shaking incu-
bation period (time differed for each test) a wash buffer was 
used to eliminate all the unbound enzymes, and a MSD 
Read Buffer was added to produce the suitable chemical 
Table 1  Patient and tumor characteristics
°Median follow-up was 65 months (range 1–96 months)
*CTC circulating tumour cell, FEC-D fluorouracil-epirubicin-cyclo-
phosphamide (500/100/500  mg/m2, FEC) followed by doxetacel 
(100  mg/mg2), FEC-DG fluorouracil-epirubicin-cyclophosphamide 
(500/100/500  mg/m2, FEC) followed by gemcitabine (1.000  mg/m2 
d1,8)-doxetaxel (75 mg/m2)
# Per 30 ml of blood







No. of patients 160 40
Age in years (mean ± SD) 54.2 ± 9.6 53.3 ± 10.1
CTC status
 CTC negative (CTC = 0#) 80 (50) 20 (50)
 CTC positive (CTC ≥ 1#) 80 (50) 20 (50)
Tumour size
 pT1a-c 78 (48.7) 10 (25.0)
 pT2-4 82 (51.3) 30 (75.0)
Lymph node status
 pN0 (node negative) 54 (33.8) 8 (20.0)
 pN1 (1–3 axillary) 82 (51.2) 12 (30.0)
 pN2 (4–9 axillary) 22(13.7) 16 (40.0)
 pN3 (≥ 10 axillary) 2 (1.3) 4 (10.0)
Grading
 G2 88 (55.0) 10 (25.0)
 G3 72 (45.0) 30 (75.0)
Hormone receptor status
 Negative 44 (27.5) 10 (25.0)
 Positive 116 (72.5) 30 (75.0)
Her2-neu status
 Negative 28 (17.5) 30 (75.0)
 Positive 132 (82.5) 10 (25.0)
Menopausal status
 Premenopausal 69 (43.1) 14 (35.0)
 Postmenopausal 91 (56.9) 26 (65.0)
Primary operation
 Breast conserving 113 (70.6) 29 (72.5)
 Mastectomy 47 (29.4) 11 (27.5)
Systematic therapy
 Chemotherapy-FEC-D 76 (47.5) 21 (52.5)
 Chemotherapy-FEC-DG 84 (52.5) 19 (47.5)
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environment for electrochemiluminescence. We then loaded 
the plate into an MSD instrument (MESO QuickPlex SQ 
120) for examination where voltage applied to the plate elec-
trodes caused the captured labels to emit light. The intensity 
of the emitted light presented a quantitative measure for the 
amount of protein of interest present in the sample [44, 45] 
(see homepage: www.mesos cale.com).
Statistical analysis
Statistical analysis was accomplished using SPSS 24.0 (IBM 
Corp., Armonk, NY, USA). The outcomes collected were 
recorded and inserted into the SPSS database in the implied 
manner. We evaluated the relationship between IL-15 and 
eotaxin and each matching criterion (CTC-positive vs. CTC-
negative; OS -survival vs. death; grade 2 vs. grade 3; lymph 
node involvement vs. no lymph node involvement; triple-
positive- vs. triple-negative breast cancer; progesterone 
receptor-positive vs. progesterone receptor-negative; oestro-
gen receptor-positive vs. oestrogen receptor-negative; HER2/
neu receptor-positive vs. HER2/neu receptor-negative) using 
the non-parametric Spearman correlation coefficient. Each 
parameter to be considered was required to have a p-value 
of less than 0.05. Statistically significant results for the 
Spearman correlation coefficient were then assessed with 
the non-parametric Mann–Whitney U rank-sum test. Moreo-
ver, variables were examined by the use of box-plot analysis. 
All statistical tests were considered significant at p < 0.05.
Results
CTC‑positive vs. CTC negative patients
In the overall patient collective, statistically significant dif-
ferences were shown for IL-15 values in regard to the CTC-
status. Amongst the CTC-negative group, those patients who 
died during the follow-up period expressed significantly 
higher levels of IL-15 compared to those patients being 
CTC-negative who were living at follow-up. This cohort 
expressed low levels of IL-15. The Spearman correlation 
coefficient assessed the p-value of 0.008 which was moreo-
ver supported by the Mann–Whitney-U-Test p = 0.008. ROC 
analysis implemented an AUC value of 0.688 (see Fig. 1a).
Furthermore, analysis amongst the CTC-positive col-
lective showed that patients who died during the follow-
up period, displayed significantly higher levels of IL-15 in 
comparison to CTC-positive patients who were living at 
follow-up; revealing expressively low levels of IL-15. The 
Spearman correlation coefficient evaluated the p-value at 
0.001 which was reinforced by the Mann–Whitney-U-Test 
p = 0.001. ROC analysis was executed, revealing an AUC 
value of 0.729 (see Fig. 1b).
Lymph node involvement
The patient collective with lymph node metastasis indicated 
statistically significant differences in regard to the patient 
survival outcome in correlation to IL-15 levels. Box-plot 
analysis showed that patients with lymph node metastasis 
who died during the follow-up period demonstrated consid-
erably increased IL-15 values in contrast to the notable low 
IL-15 levels in patients with lymph node metastasis who 
were living at follow-up. The spearman correlation coef-
ficient calculated the p-value at 0.001 which was further-
more confirmed by the Mann–Whitney-U-Test p = 0.001. 
ROC analysis assessed the AUC value at 0.697 (see Fig. 2a).
Moreover, a statistically significant correlation was also 
proven for the collective with no lymph node metastasis in 
association to the IL-15 levels and patient survival. The box 
plot analysis revealed that the collective of patients with 
no lymph node involvement (N0) who nonetheless died in 
the follow-up period, demonstrated significantly higher lev-
els of IL-15 values in distinction to the notable low IL-15 
levels in patients who remained alive. The Spearman cor-
relation coefficient evaluated the p-value at 0.013 which 
was furthermore supported by the Mann–Whitney U Test 
p = 0.014. ROC analysis was executed, revealing an AUC 
value at 0.755 (see Fig. 2b).
Hormone receptor status
In the total patient collective, statistically significant differ-
ences were shown for IL-15 values regarding the hormone 
receptor status. Patients with a triple-negative breast cancer 
(TNBC; progesterone receptor negative, oestrogen recep-
tor negative, HER-2-neu receptor negative) who died dur-
ing the follow-up period, expressed drastically higher levels 
of IL-15 as opposed to decreased IL-15 levels in patients 
who remained alive and showed a positive OS and DFS. 
The Spearman correlation coefficient assessed the p-value 
at 0.011, supported by the Mann–Whitney U Test p = 0.010. 
ROC analysis was executed, revealing an AUC value of 
0.779 (see Fig. 3a).
Finally, patients with triple-positive breast cancer who 
died while showing poor OS and DFS also displayed sig-
nificantly higher levels of IL-15, in contrast to those patients 
who remained alive with a triple-positive breast cancer. The 
latter showing significantly low IL-15 levels. The Spear-
man correlation coefficient disclosed a p-value of 0.002. 
Mann–Whitney-U-Test calculated p = 0.003. ROC analysis 
gave an AUC value of 0.681 (see Fig. 3b).
Grading
The data collected implies statistically significant differ-
ences concerning IL-15 levels in patients with a Grade 3 
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tumor (G3) in respect to OS and DFS. Patients with a G3 
tumor, who died in the follow-up period, showed consid-
erably increased IL-15 values, in contrast to the signifi-
cantly decreased IL-15 levels in patients with G3 tumor 
with favourable OS and DFS and were living at follow-up. 
The Spearman correlation coefficient evaluated the p-value 
at 0.001, furthermore underlined by the Mann–Whitney-
U-Test p = 0.001. ROC analysis revealed an AUC value of 
0.725 (see Fig. 4).
Patient survival
Analysing the patient collective who remained alive in the 
follow-up period in regards to patient survival, showed sta-
tistically significant differences in eotaxin values in correla-
tion to the CTC status. The box-plot analysis revealed that 
the living patient collective, being CTC-negative, display 
higher levels of eotaxin compared to the reduced values 
of eotaxin in the living patient group, being CTC-positive. 
Fig. 1  a Box plot analysis of Interleukin 15 expression (IL-15) in the 
sera of patients with CTC-negative breast cancer. IL-15 release was 
significantly higher in patients who died compared to patients who 
were living at follow-up (p = 0.008). Receiver operator curve analysis 
of sensitivity versus specificity gave an area under the curve (AUC) 
of 0.688 (a). b Box plot analysis of IL-15 expression and patients 
with CTC-positive disease. IL-15 release was expressively higher in 
the patient collective who died in the follow-up period compared to 
the living patient group (p = 0.001). Receiver operator curve analy-
sis of sensitivity versus specificity gave an AUC of 0.729. The range 
amongst the 25th and 75th percentiles is demonstrated by boxes with 
a horizontal line at the median. The bars display the 5th and 95th per-
centiles. Circles specify values more than 1.5 box lengths. Asterisks 
specify values (marked with a number) more than 3.0 box lengths 
from the 75th percentile
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The Spearman correlation coefficient assessed the p-value 
at 0.017 which was also supported by the Mann–Whitney-
U-Test p = 0.016. To continue, ROC analysis was performed, 
displaying an AUC value of 0.609 (see Fig. 5).
Discussion
Within this study we analyzed the distribution of IL-15 and 
eotaxin concentrations and reveal the differences in their 
expression in the sera of breast cancer patients with and 
without circulating tumor cells. Prior studies have estab-
lished the role of IL-15 in various tumor identities such as 
haematological malignancies [38, 46–48], colon cancer [32] 
or prostate cancer [49]. A clinical trial concerning adult 
acute lymphoblastic leukaemia even specified that higher 
IL-15 concentration was significantly associated with a 
poorer outcome and decreased survival rates compared to 
decreased serum concentrations of IL-15 in the control 
group of normal healthy individuals [48]. IL-15 levels are 
being discussed to be used as a specific tumor biomarker for 
prognostic values [28, 46]. Nevertheless, the prognostic role 
Fig. 2  a Box plot analysis of IL-15 expression in the sera of patients 
with lymph node metastasis who died in the follow-up period, dem-
onstrate considerably increased IL-15 values in contrast to the nota-
ble low IL-15 levels in patients with lymph node metastasis who were 
living up to follow-up (p = 0.001). b Box plot analysis showing the 
collective of patients with no lymph node involvement (N0) that died 
during the follow-up period. This group demonstrate significantly 
higher levels of IL-15 in contrast to the significantly decreased IL-15 
levels in patients who remained alive (p = 0.014). The range amongst 
the 25th and 75th percentiles is demonstrated by boxes with a hori-
zontal line at the median. The bars display the 5th and 95th percen-
tiles. Circles specify values more than 1.5 box lengths. Asterisks 
specify values (marked with a number) more than 3.0 box lengths 
from the 75th percentile. Receiver operator curve analysis of sensitiv-
ity versus specificity gave an area under the curve (AUC) of 0.697 (a) 
and 0.755 (b), respectively
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of IL-15 in breast cancer remains uncertain. In this study, 
we found that the serum concentration of IL-15 in breast 
cancer patients was significantly increased amongst those 
patients with poor OS and DFS and who had died at follow-
up. In the overall patient collective, and regardless of their 
CTC-status, lymph node involvement or hormone receptor 
status, those patients with the poorest OS and DFS expressed 
significantly higher levels of serum IL-15 compared to those 
patients with the best survival outcome, which showed low 
IL-15 concentrations. Nevertheless, elevated serum concen-
trations of IL-15 significantly correlate to those patients with 
a Grade 3 tumor. Patients with poor OS who died during the 
follow-up period demonstrated considerably increased IL-15 
values in contrast to the significantly low IL-15 levels in 
patients with a Grade 3 tumor and positive survival outcome. 
IL-15 values were also significantly decreased in patients 
with a Grade 2 tumor.
However, studies have indicated that IL-15 can lead to 
both a favourable and an unfavourable diagnosis, differing 
by the type of tumor. It is predicted that the inconsist-
ent function of IL-15 in tumors lies within the different 
immune effects or single nucleotide polymorphism [46]. 
Fig. 3  a Box plot analysis of IL-15 expression in the sera of patients 
with triple-negative breast cancer. Amongst this patient group, 
deceased patients expressed drastically higher levels of IL-15 com-
pared to decreased IL-15 values in patients who remained alive 
(p = 0.011). b Similarly, we preformed a box plot analysis of IL-15 
expression in the sera of patients with triple-positive breast cancer. 
Those patients with poor OS and DFS also displayed significantly 
higher levels of IL-15 in contrast to those patients who remained 
alive with a triple-positive breast cancer (p = 0.002). The range 
amongst the 25th and 75th percentiles is demonstrated by boxes with 
a horizontal line at the median. The bars display the 5th and 95th per-
centiles. Circles specify values more than 1.5 box lengths. Asterisks 
specify values (marked with a number) more than 3.0 box lengths 
from the 75th percentile. Receiver operator curve analysis of sensitiv-
ity versus specificity gave an area under the curve (AUC) of 0.779 (a) 
and an AUC of 0.681 (b)
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Fig. 4  Box plot analysis of IL-15 expression in the sera of patients 
with G3 tumor. IL-15 release was significantly higher in the G3 
patient collective who died during the follow-up period in contrast 
to low IL-15 levels in living patients at follow up with a G3 tumor 
(p = 0.001). The range amongst the 25th and 75th percentiles is dem-
onstrated by boxes with a horizontal line at the median. The bars dis-
play the 5th and 95th percentiles. Circles specify values more than 
1.5 box lengths. Asterisks specify values (marked with a number) 
more than 3.0 box lengths from the 75th percentile. Receiver operator 
curve analysis of sensitivity versus specificity gave an area under the 
curve (AUC) of 0.725
Fig. 5  Box plot analysis of eotaxin expression in the sera of patients 
who remained alive up to follow-up. The patient group with the 
most favourable OS and DFS, furthermore CTC-negative, express 
increased eotaxin values compared to the reduced levels of eotaxin 
in the living patient group being CTC-positive (p = 0.016). The range 
amongst the 25th and 75th percentiles is demonstrated by boxes with 
a horizontal line at the median. The bars display the 5th and 95th per-
centiles. Circles specify values more than 1.5 box lengths. Asterisks 
specify values (marked with a number) more than 3.0 box lengths 
from the 75th percentile. Receiver operator curve analysis of sensitiv-
ity versus specificity gave an area under the curve (AUC) of 0.609
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Rohena-Rivera et al. for example focused on determin-
ing the role of IL-15 in prostate cancer using in vitro and 
in vivo models by administrating IL-15 injections directly 
into the tumor tissue [49]. Blum et al. suggested that the 
presence of IL-15 caused inflammation, increased neu-
trophil infiltration, decreased the number of blood ves-
sels, and was thus positively associated with biochemical 
recurrent-free survival in prostate cancer patients [50]. 
Nevertheless, these studies focused on the microenviron-
ment of the tumor itself, suggesting that IL-15 expres-
sion, when found in the microenvironment, may provide 
a benefit for patients [49, 51]. Similarly, Kunivasu et al. 
defined IL-15 as a stimulus and attractant to Natural Killer 
T-cells (NK) and its expression is subsequently considered 
to be a protective trigger against the progression of certain 
tumor identities [30, 31, 35, 52]. Nevertheless, it has also 
been proven that in progressive tumors the infiltration of 
NK-cells into neoplasms suppressed the activity of the 
NK-cells [33, 34, 53]. Kunivasu et al. described IL-15 to 
have an opposite biological effect in colon cancer cells to 
that in the host immune system. IL-15 expressed on colon 
epithelial cells and cancer cells can promote the growth 
of cancer cells [23, 32, 54], while its stimulation on NK 
cells has an antitumor effect [35, 55]. Our study has shown 
that in this scenario both the IL-15-producing breast can-
cer cell and the patients’ host immune system producing 
IL-15, show a pro-tumor effect and promote tumor pro-
gression and metastasis. Our data indicate that when IL-15 
can be detected in the sera of patients, its presence might 
contribute to the process of angiogenesis and progression 
of the disease thus resulting in a poorer survival outcome.
The association and exact mechanism of increased 
serum IL-15 levels and unfavourable prognosis are nev-
ertheless not well defined so far. Numerous hypothetical 
justifications have however been proposed. IL-15 has 
been described to cause an increased invasion of inflam-
matory cells to the tumor site and proliferation of adi-
pocytes that consequently cause an increase in size. In 
addition to the proliferation effect of IL-15, studies on 
the metastatic potential have shown an up-regulation of 
desmin and a-sma expression, both markers suggesting a 
stimulation to metastasis through IL-15 [49]. These results 
support our findings of increased IL-15 levels in deceased 
patients. IL-15 in in vitro and in vivo studies has been 
proven to increase the tumor volume as a consequence 
of inflammation and lipid mobilization [49, 56]. Wang 
et al. described the cell proliferation caused by IL-15, is 
mechanically induced by a strong proliferative signal by 
the JAK/STAT and Ras/MAPK pathway, and by increasing 
the anti-apoptotic proteins Bcl-2 and Bcl-Xl it can inhibit 
cell death [46, 57]. Furthermore, IL-15 decreases pro-
apoptotic proteins such as BIM, PUMA by the activation 
of the PI3 K pathway [58–61]. Conversely, to reveal the 
exact biochemical and cellular function of IL-15 mediated 
stimulation in breast cancer, additional studies are needed.
IL-15 is a member of the 4 alpha helix group of cytokines, 
acting via its effective specific receptor IL-15Rα, that is 
expressed on antigen-presenting dendritic cells, monocytes 
and macrophages [62]. IL-15 demonstrates wide-ranging 
activity and can induce the differentiation and prolifera-
tion of T- B- and NK cells. IL-15 is furthermore known 
to stimulate the differentiation and immunoglobulin syn-
thesis by B cells and has the ability to induce maturation 
of DCs [24, 62]. Studies have shown that DCs could cause 
this discrepancy of IL-15 levels acting both as a positive 
or a negative marker in regard to tumor evolution and sur-
vival outcome and its effect on the Immune system [63–65]. 
DCs, one of the most crucial components of the antigen-
presenting stimulation pathway can have a massive impact 
on the regulation of anti-tumor immune responses [41]. DC 
based immunotherapies, thoroughly tested in liver cancer, 
are believed to contribute to the eradication of residual and 
recurrent tumor cells. It was suggested that mature DCs 
stimulated with OK432 produce large amounts of T helper 
type 1 (Th1) cytokines [66]. IL-15 is known to prime T 
lymphocytes and NK cells when secreted by DCs and to 
then stimulate anti-tumor immune responses [67, 68]. Stud-
ies have focused on enhancing tumor antigen presentation to 
T lymphocytes by transferring activated DCs with major his-
tocompatibility, co-stimulatory molecules and loaded with 
tumor-associated antigens [69–73]. It has been suggested 
that transferred activated DCs result in higher concentrations 
of IL-15 and the chemokine eotaxin in the tumor, and collec-
tively proposes that a DC-based, active immunotherapeutic 
strategy in combination with loco-regional treatment exerts 
beneficial anti-tumor effects against liver cancer and in DFS 
[63]. In contrast, it was reported that immature DC infused 
precisely into tumor tissues also contributed to the recruit-
ment and activation of immune cells such as IL-15 in situ, 
however, this approach by itself generated limited anti-tumor 
effects due to probably insufficient stimulation of immature 
DCs [63, 74] and had no effect on prolonged recurrence-free 
survival. These studies therefore propose that the cytokine 
profile expressed by dendritic cells is dependent on the cell 
subtype and mode of activation whereas the concentration 
and presence of IL-15 itself does not correlate with a ben-
eficial anti-tumor effect but indicates a close relation to the 
effectiveness of the DCs in regard to preventing tumor cell 
growth and survival.
On the other hand, eotaxin is known to selectively recruit 
eosinophils, act as a chemo-attractant, playing a major role 
in the inhibition of pro-angiogenetic factors, and thus result-
ing in an anti-tumor effect [39, 40, 75]. Eotaxin has been 
described to act as an important factor in the down regula-
tion of angiogenesis by decreasing the stimulus for neo-vas-
cularisation [76]. The development of invasive, aggressive 
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and metastatic breast cancer is essentially reliant on the 
neo-vascularisation to provide blood supply for the nourish-
ment and progress of the tumor. Accordingly, the increased 
eotaxin concentrations in the CTC negative collective could 
cause a significant interruption of tumor vascularization thus 
preventing CTCs being released into the peripheral blood 
by inhibiting circulation specific metastasis. A noteworthy 
delay in tumor growth could ensue in the absence of CTCs in 
those patients, subsequently enhancing survival and result-
ing in a favourable outcome.
The limitation of this study is the relatively short median 
follow-up period of 65 months. As previously described by 
Rack et al., the relative short follow-up period in the context 
of good prognosis results in minor absolute differences in the 
rate of recurrence and death. Further limitations are the lack 
of data on Ki-67 in the patient collective. This could be an 
advantage for more accurate subdivision of different breast 
cancer subtypes. The disproportional distribution of patient 
samples, considering 160 living patients, at last observation, 
and 40 deceased patients at the end of the follow-up period, 
could lead to limited statistical power. The limited sample 
size of 200 patients can be regarded as a limitation itself. 
It would be of interest to test for chemokine and cytokine 
levels in the overall collective of the SUCCES study group.
To sum up, accumulating evidence suggests IL-15 can 
initiate and promote certain types of malignancies. None-
theless, an anti-tumour effect of IL-15 on the immune 
system has also been hypothesized in experimental tri-
als [67, 68] and the activation of IL-15 is currently of 
major interest in several clinical Phase I trials [63, 74]. 
Tinhofer et al. have explored the expression patterns of the 
particularly sensitive IL-15 signalling pathway for mul-
tiple myeloma, a disease defined by the accumulation of 
malignant plasma cells in the bone marrow. Since IL-15 
is also up-regulated in the sera of patients with multiple 
myeloma, it has been found that those malignant plasma 
cells expressed all three components of the IL-15R hetero-
trimer [26–28]. In contrast, normal B-cells from healthy 
donors downregulate IL-15Rα in response to IL-15. IL-15 
overexpression in malignant plasma cells in in-vitro stud-
ies suggests a protection from spontaneous apoptosis and 
initiation of induced cell death [26–28, 38]. The data, sim-
ilarly to our findings, imply that breast cancer and multiple 
myeloma cells are likely to reduce apoptosis and fortify 
themselves via autocrine IL-15 stimulation, thus becom-
ing less dependent upon their microenvironment. In order 
to clarify the exact cellular mechanism of IL-15 resolved 
signalling in breast cancer, further studies are needed. 
Early trials in several solid tumors are showing significant 
clinical responses in patients who are treated with agents 
that block negative regulators of T cell activation [69–73]. 
Nonetheless it is suggested that chronic stimulation can 
lead to malignant transformation of T and NK cells and 
appear to encourage its oncogenic properties. Exploit-
ing IL-15′s influential properties to improve lymphocyte 
effector function in the setting of malignancy is likely to 
become more structured in the future and might lead to a 
broader use in the treatment of tumor malignancies.
These findings for the first time demonstrate the func-
tional interaction of increased IL-15 concentrations in the 
peripheral blood and poor OS and DFS, regardless of the 
CTC status, lymph node metastasis, or hormone receptor 
status. A close relationship of increased IL-15 levels in 
patients with a Grade 3 breast tumor and those with the 
poorest survival outcome were moreover confirmed. These 
outcomes imply a substantial function of IL-15 in the patho-
genesis of breast cancer and thus could offer new insights 
into tumor evolution and possible therapeutic approaches. 
Serum IL-15, simply measured in the everyday clini-
cal routine, could therefore be an independent prognostic 
marker of major importance in terms of DFS and OS for 
breast cancer patients. The immense impact of IL-15 as an 
independent marker for predicting the survival outcome is 
furthermore underlined by the fact that even in the patient 
collective with favourable tumor characteristics at primary 
diagnosis, such as CTC negativity, no lymph node involve-
ment or triple-positive breast cancer, and increased serum 
IL-15 concentrations were significantly increased in those 
patients that deceased. Bearing this in mind, IL-15 could 
be used as an early marker to highlight high-risk patients 
and the subsequent adjustment of the cancer therapy strat-
egy. In contrast, it can also prevent over treatment in those 
patients with decreased IL-15 levels. The increased levels 
of the chemokine eotaxin in CTC negative patients with the 
best OS and DFS outcome on the other hand, suggests that 
the overexpression in tumor cells inhibits CTCs entering 
the peripheral blood, thus emphasizing a significant anti-
angiogenic effect, inhibiting tumor growth and metastasis. 
Furthermore, in regard to CTC negativity, the eotaxin value 
may potentially serve as a predictive marker.
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